Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme
Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method: Baseline audit against evidence‐based standards, followed by provision of benchmarked data and a range o...
Saved in:
| Published in | Acta psychiatrica Scandinavica Vol. 118; no. 1; pp. 26 - 33 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.07.2008
Blackwell |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0001-690X 1600-0447 1600-0447 |
| DOI | 10.1111/j.1600-0447.2008.01203.x |
Cover
Loading…
| Abstract | Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics.
Method: Baseline audit against evidence‐based standards, followed by provision of benchmarked data and a range of change interventions, with re‐audit 1 year later.
Results: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re‐audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re‐audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia.
Conclusion: The programme’s success may be partly attributed to the use of a widely‐accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. |
|---|---|
| AbstractList | The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics.
Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later.
At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia.
The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method: Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later. Results: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. Conclusion: The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. [PUBLICATION ABSTRACT] Objective:The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method:Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1year later. Results:At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. Conclusion:The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method: Baseline audit against evidence‐based standards, followed by provision of benchmarked data and a range of change interventions, with re‐audit 1 year later. Results: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re‐audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re‐audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. Conclusion: The programme’s success may be partly attributed to the use of a widely‐accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics.OBJECTIVEThe aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics.Baseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later.METHODBaseline audit against evidence-based standards, followed by provision of benchmarked data and a range of change interventions, with re-audit 1 year later.At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia.RESULTSAt baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re-audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re-audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia.The programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams.CONCLUSIONThe programme's success may be partly attributed to the use of a widely-accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics. Method: Baseline audit against evidence‐based standards, followed by provision of benchmarked data and a range of change interventions, with re‐audit 1 year later. Results: At baseline, 48 assertive outreach teams across the UK submitted data on screening over the previous year for 1966 patients. At re‐audit, 35 of the teams submitted data for 1516 patients. Screening for all four aspects of the metabolic syndrome (measuring blood pressure, obesity, blood glucose and plasma lipids) had increased significantly by re‐audit. Clinical variables increasing the likelihood of full screening were clozapine treatment and a known diagnosis of diabetes or dyslipidaemia. Conclusion: The programme’s success may be partly attributed to the use of a widely‐accepted audit standard, and bespoke change interventions that directly addressed barriers to screening identified by the participating clinical teams. |
| Author | Barnes, T. R. E. Cavanagh, M.-R. Taylor, D. Hancock, E. Lelliott, P. Paton, C. |
| Author_xml | – sequence: 1 givenname: T. R. E. surname: Barnes fullname: Barnes, T. R. E. organization: Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus – sequence: 2 givenname: C. surname: Paton fullname: Paton, C. organization: Department of Psychological Medicine, Imperial College Faculty of Medicine, Charing Cross Campus – sequence: 3 givenname: E. surname: Hancock fullname: Hancock, E. organization: Royal College of Psychiatrists' Centre for Quality Improvement – sequence: 4 givenname: M.-R. surname: Cavanagh fullname: Cavanagh, M.-R. organization: Royal College of Psychiatrists' Centre for Quality Improvement – sequence: 5 givenname: D. surname: Taylor fullname: Taylor, D. organization: South London and Maudsley NHS Foundation Trust, London, UK – sequence: 6 givenname: P. surname: Lelliott fullname: Lelliott, P. organization: Royal College of Psychiatrists' Centre for Quality Improvement |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20435643$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18582345$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkktvEzEUhUeoiKaFv4AsJNhNsMf2PFggVRG0oPKQCgo7645zp3WYsVPbgWTJP8fThCy6Kd7YV_7OuX6ck-zIOotZRhidsjReL6espDSnQlTTgtJ6SllB-XTzKJscNo6yCaWU5WVDfxxnJyEsUykZrZ9kx6yWdcGFnGR_rrRHtMZek855Em-QDBihdb3RJGztwrsBibFEu2FYWxO3ZBW2-sZA9IlYQTRoYyArj0F70-KCgI3mjnHR6PCGALldQz8qzbDy7hcOSZEE7trDMODT7HEHfcBn-_k0-_7-3bfZRX755fzD7Owy11IInjNodcEXHRTNggvaNgiNLrumYdBUFXJkFKAtGEPKaMeZENDRAiotsK1lh_w0e7XzTZ1v1xiiGkzQ2Pdg0a2DKpuiZJKxB0HWVLISdZ3AF_fApVt7my6RGFnLqpRFgp7voXU74EKtvBnAb9W_L0jAyz0AQUPfebDahANXUMFlKXji3u447V0IHjulTUzP72z0YHrFqBqzoZZqjIAaI6DGbKi7bKhNMqjvGRzO8rB03_u36XH73zp1Nvt6NS6TQb4zMCHi5mAA_qcqK15JNf98ruSnqrwo53P1kf8Fc5niLQ |
| CODEN | APYSA9 |
| CitedBy_id | crossref_primary_10_1186_s13012_017_0663_z crossref_primary_10_1192_pb_bp_110_030106 crossref_primary_10_1016_j_psym_2012_07_008 crossref_primary_10_1177_0269881110391123 crossref_primary_10_1111_inm_12085 crossref_primary_10_1071_PY11045 crossref_primary_10_1186_1745_6215_12_167 crossref_primary_10_2217_clp_10_29 crossref_primary_10_1177_2042018812458697 crossref_primary_10_1192_bjp_bp_111_094334 crossref_primary_10_3109_10398561003692571 crossref_primary_10_1097_YCO_0b013e328325a585 crossref_primary_10_1177_1359786810374863 crossref_primary_10_2217_npy_11_54 crossref_primary_10_1177_1078390315598607 crossref_primary_10_3109_09540261_2011_606541 crossref_primary_10_1192_bjp_195_52_s1 crossref_primary_10_1186_s12888_015_0416_y crossref_primary_10_3109_00048674_2011_595370 crossref_primary_10_1192_pb_bp_109_026864 crossref_primary_10_1093_schbul_sbu006 crossref_primary_10_1136_bmjopen_2015_007633 crossref_primary_10_9758_cpn_2023_21_1_126 crossref_primary_10_1177_0004867414548903 crossref_primary_10_1200_JCO_2017_76_0462 crossref_primary_10_1007_s10597_015_9833_0 crossref_primary_10_1192_bjp_bp_108_051979 crossref_primary_10_1007_s10488_024_01408_9 crossref_primary_10_3390_medicina59122052 crossref_primary_10_1007_s00127_012_0546_1 crossref_primary_10_1186_s13643_021_01586_9 crossref_primary_10_1016_j_japh_2021_04_010 crossref_primary_10_1111_ajr_12270 crossref_primary_10_1176_ps_62_11_pss6211_1338 crossref_primary_10_1192_bjp_195_52_s37 crossref_primary_10_1016_j_apnu_2017_09_002 crossref_primary_10_1176_appi_ps_201900108 crossref_primary_10_1186_s13063_016_1176_9 crossref_primary_10_1111_j_1365_2834_2009_00977_x crossref_primary_10_1093_schbul_sbv101 crossref_primary_10_1016_j_encep_2012_10_009 crossref_primary_10_1111_inm_12301 crossref_primary_10_3109_01612840_2014_901449 crossref_primary_10_1177_0269881116645254 crossref_primary_10_1177_1039856215608285 crossref_primary_10_1192_bjp_bp_112_112383 crossref_primary_10_1017_S003329171100105X crossref_primary_10_3310_pgfar07020 crossref_primary_10_1517_14656566_2010_499125 crossref_primary_10_1186_s40814_018_0333_1 crossref_primary_10_1016_j_schres_2010_11_015 crossref_primary_10_1097_NMD_0000000000000906 crossref_primary_10_1002_pds_1492 crossref_primary_10_1177_2045125314560734 crossref_primary_10_1136_bmjopen_2017_018181 crossref_primary_10_3109_08039488_2012_732115 crossref_primary_10_7189_jogh_14_04074 crossref_primary_10_2217_npy_11_24 crossref_primary_10_1007_s10597_016_0007_5 crossref_primary_10_1007_s10803_016_2712_x |
| Cites_doi | 10.1017/S0033291798008186 10.1111/j.1464-5491.2006.01858.x 10.2337/diacare.27.2.596 10.1016/j.schres.2005.12.855 10.1080/07853890410031849 10.1016/j.schres.2005.07.014 10.1001/jama.285.19.2486 10.1001/archpsyc.64.2.242 10.1016/j.schres.2006.08.017 10.1016/j.schres.2007.12.487 10.5694/j.1326-5377.2004.tb06443.x 10.1097/01.yic.0000188215.84784.17 10.1001/jama.287.3.356 10.1192/bjp.185.2.152 10.1136/bmj.332.7545.833 10.1176/appi.ps.57.1.21 10.1192/bjp.184.47.s80 10.1002/chp.1340240506 10.1093/schbul/sbm038 10.1210/jc.2007-1167 10.1111/j.1600-0447.2004.00372.x 10.1177/070674370404901106 10.1136/ebmh.6.1.6 10.4088/JCP.v64n0513 10.1176/ajp.2006.163.7.1273 10.1111/j.1464-5491.2007.02244.x 10.4088/JCP.v68n0711 10.1192/bjp.bp.106.031716 10.1002/14651858.CD000259.pub2 10.1080/00048670701392841 10.4088/JCP.v65n0415 10.1192/apt.10.6.403 10.1161/01.CIR.0000111245.75752.C6 10.4088/JCP.v68n0103 10.1177/0269881105049039 10.1002/14651858.CD003030 |
| ContentType | Journal Article |
| Copyright | Copyright © 2008 The Authors. Journal Compilation © 2008 Blackwell Munksgaard 2008 INIST-CNRS Journal compilation © 2008 Blackwell Munksgaard |
| Copyright_xml | – notice: Copyright © 2008 The Authors. Journal Compilation © 2008 Blackwell Munksgaard – notice: 2008 INIST-CNRS – notice: Journal compilation © 2008 Blackwell Munksgaard |
| CorporateAuthor | on behalf of the UK Prescribing Observatory for Mental Health UK Prescribing Observatory for Mental Health |
| CorporateAuthor_xml | – name: on behalf of the UK Prescribing Observatory for Mental Health – name: UK Prescribing Observatory for Mental Health |
| DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 |
| DOI | 10.1111/j.1600-0447.2008.01203.x |
| DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1600-0447 |
| EndPage | 33 |
| ExternalDocumentID | 1494244171 18582345 20435643 10_1111_j_1600_0447_2008_01203_x ACPS1203 ark_67375_WNG_5M76H6WW_J |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom Europe United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom--UK |
| GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACHQT ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EAD EAP EAS EBC EBD EBS EJD EMB EMK EMOBN EPS ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 UPT V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YF5 ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7TK K9. 7X8 |
| ID | FETCH-LOGICAL-c5443-1abc23dfa29d340b9ea9c6f991a977e3e10aab211e010f3144af02a7c4eb85fe3 |
| IEDL.DBID | DR2 |
| ISSN | 0001-690X 1600-0447 |
| IngestDate | Fri Sep 05 13:24:36 EDT 2025 Tue Aug 05 10:56:21 EDT 2025 Thu Aug 14 02:51:15 EDT 2025 Mon Jul 21 06:04:38 EDT 2025 Mon Jul 21 09:13:46 EDT 2025 Thu Apr 24 22:58:14 EDT 2025 Tue Jul 01 01:06:38 EDT 2025 Wed Jan 22 17:09:34 EST 2025 Wed Oct 30 09:56:43 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Endocrinopathy Social environment Human Sanitary program screening Psychotropic Neuroleptic Toxicity Mental health Pharmacotherapy Metabolic diseases Cardiovascular disease Medical screening Metabolic syndrome Audit Treatment Follow up study Mental disorder antipsychotics Community treatment Public health |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5443-1abc23dfa29d340b9ea9c6f991a977e3e10aab211e010f3144af02a7c4eb85fe3 |
| Notes | ark:/67375/WNG-5M76H6WW-J istex:CDAC11FCC9A43CC5C8938F6CCF9AFA289CC0320E ArticleID:ACPS1203 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1600-0447.2008.01203.x |
| PMID | 18582345 |
| PQID | 195857652 |
| PQPubID | 33508 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_69261511 proquest_miscellaneous_19757488 proquest_journals_195857652 pubmed_primary_18582345 pascalfrancis_primary_20435643 crossref_citationtrail_10_1111_j_1600_0447_2008_01203_x crossref_primary_10_1111_j_1600_0447_2008_01203_x wiley_primary_10_1111_j_1600_0447_2008_01203_x_ACPS1203 istex_primary_ark_67375_WNG_5M76H6WW_J |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | July 2008 |
| PublicationDateYYYYMMDD | 2008-07-01 |
| PublicationDate_xml | – month: 07 year: 2008 text: July 2008 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: United States – name: Aalborg |
| PublicationTitle | Acta psychiatrica Scandinavica |
| PublicationTitleAlternate | Acta Psychiatr Scand |
| PublicationYear | 2008 |
| Publisher | Blackwell Publishing Ltd Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
| References | Suvisaari JM, Saarni SI, Perala J et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-1055. Van Nimwegen LJ, Storosum JG, Blumer RM et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008;93:572-577. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002, Clinical Guideline 1, available at: http://www.nice.org.uk. Brown MJ. Hypertension and ethnic group. Br Med J 2006;332:833-836. Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007;41:606-610. Brown S, Birtwistle J, Roe L et al. The unhealthy lifestyles of people with schizophrenia. Psychol Med 1999;29:697-701. Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-98. American Diabetes Association & American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100. Expert Panel on Detection and Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008 doi:DOI: 10.1016/j.schres.2007.12.487; [Epub ahead of print]. Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242-249. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579. Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007;68:22-28. Diaz VA, Mainous AG III, Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007;24:1199-1204. Grundy SM, Brewer HB, Cleeman JL et al. Definition of the metabolic syndrome. Circulation 2004;109:433-438. Laaksonen DE, Niskanen L, Lakka H-M, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004;36:332-346. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl. 4):8-13. De Hert MA, Van Winkel R, Van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760. Patrick V, Schleifer SJ, Nurenberg JR et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006;57:21-23. Taylor D, Young C, Esop R et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;85:152-156. Taylor D, Young C, Esop R et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-186. Drake RE, Torrey WC, McHugo GJ. Strategies for implementing evidence-based practices in routine mental health settings. Evid Based Ment Health 2003;6:6-7. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480. Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence and future implications. J Contin Educ Health Prof 2004;24(suppl. 1):S31-S37. Lamberti JS, Olson D, Crilly JF et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276. Paton C, Esop R, Young C et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305. Saari K, Koponen H, Laitinen J et al. Hyperlipidaemia in persons using antipsychotic medication: a general population based birth cohort study. J Clin Psychiatry 2004;65:547-550. Lambert TJR, Chapman LH on behalf of the Consensus Working Group (2004) Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004;181:544-548. McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia : Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES 111. Schizophr Res 2005;80:19-32. Haddad PM. Antipsychotics and diabetes: review of -prospective data. Br J Psychiatry 2004;184:S80-S86. Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM on behalf of the UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007;33:1397-1401. Rowlands P. The NICE schizophrenia guidelines: the challenge of implementation. Adv Psychiatr Treat 2004;10:403-412. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007;191:23-29. 2004; 65 2004; 85 2001; 285 2004; 181 2006; 57 2004; 27 2004; 49 1999; 29 2004; 184 2004; 24 2008 2006 2005; 80 2007; 191 2003 2002 2004; 109 2007; 33 2008; 93 2006; 332 2004; 10 2004; 110 2005; 19 2006; 83 2006; 23 2001 2006; 21 2004; 36 2003; 6 2002; 287 2006; 163 2007; 41 2007; 64 2007; 89 2007; 68 2003; 64 2007; 24 e_1_2_9_30_2 e_1_2_9_10_2 e_1_2_9_33_2 e_1_2_9_34_2 e_1_2_9_12_2 e_1_2_9_31_2 e_1_2_9_11_2 e_1_2_9_32_2 e_1_2_9_14_2 e_1_2_9_37_2 e_1_2_9_38_2 e_1_2_9_16_2 e_1_2_9_35_2 e_1_2_9_15_2 e_1_2_9_36_2 e_1_2_9_39_2 e_1_2_9_19_2 e_1_2_9_40_2 Expert Panel on Detection and Evaluation and Treatment of High Blood Cholesterol in Adults (e_1_2_9_17_2) 2001; 285 e_1_2_9_21_2 e_1_2_9_20_2 Barnes TRE (e_1_2_9_2_2) 2003 e_1_2_9_23_2 e_1_2_9_22_2 e_1_2_9_7_2 e_1_2_9_6_2 e_1_2_9_5_2 e_1_2_9_4_2 Newcomer JW (e_1_2_9_13_2) 2007; 68 e_1_2_9_3_2 e_1_2_9_9_2 e_1_2_9_8_2 e_1_2_9_25_2 e_1_2_9_24_2 e_1_2_9_27_2 e_1_2_9_26_2 National Institute for Clinical Excellence (e_1_2_9_18_2) 2002 e_1_2_9_29_2 e_1_2_9_28_2 |
| References_xml | – reference: Van Nimwegen LJ, Storosum JG, Blumer RM et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008;93:572-577. – reference: Meyer JM, Davis VG, Goff DC et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 2008 doi:DOI: 10.1016/j.schres.2007.12.487; [Epub ahead of print]. – reference: Grimshaw J, Eccles M, Tetroe J. Implementing clinical guidelines: current evidence and future implications. J Contin Educ Health Prof 2004;24(suppl. 1):S31-S37. – reference: Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007;64:242-249. – reference: Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68(suppl. 4):8-13. – reference: Lambert TJR, Chapman LH on behalf of the Consensus Working Group (2004) Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004;181:544-548. – reference: Brown MJ. Hypertension and ethnic group. Br Med J 2006;332:833-836. – reference: Grundy SM, Brewer HB, Cleeman JL et al. Definition of the metabolic syndrome. Circulation 2004;109:433-438. – reference: Haddad PM. Antipsychotics and diabetes: review of -prospective data. Br J Psychiatry 2004;184:S80-S86. – reference: Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry 2007;41:606-610. – reference: Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007;68:22-28. – reference: Barnes TRE, Paton C, Cavanagh M-R, Hancock E, Taylor DM on behalf of the UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull 2007;33:1397-1401. – reference: Expert Panel on Detection and Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497. – reference: McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia : Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES 111. Schizophr Res 2005;80:19-32. – reference: National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. 2002, Clinical Guideline 1, available at: http://www.nice.org.uk. – reference: Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579. – reference: American Diabetes Association & American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601. – reference: Taylor D, Young C, Esop R et al. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. J Psychopharmacol 2005;19:182-186. – reference: Diaz VA, Mainous AG III, Baker R, Carnemolla M, Majeed A. How does ethnicity affect the association between obesity and diabetes? Diabet Med 2007;24:1199-1204. – reference: Saari K, Koponen H, Laitinen J et al. Hyperlipidaemia in persons using antipsychotic medication: a general population based birth cohort study. J Clin Psychiatry 2004;65:547-550. – reference: Drake RE, Torrey WC, McHugo GJ. Strategies for implementing evidence-based practices in routine mental health settings. Evid Based Ment Health 2003;6:6-7. – reference: De Hert MA, Van Winkel R, Van Eyck D et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93. – reference: Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359. – reference: Hägg S, Lindblom Y, Mjörndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-98. – reference: Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier N. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 2007;191:23-29. – reference: Suvisaari JM, Saarni SI, Perala J et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007;68:1045-1055. – reference: Paton C, Esop R, Young C et al. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305. – reference: Laaksonen DE, Niskanen L, Lakka H-M, Lakka TA, Uusitupa M. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004;36:332-346. – reference: Rowlands P. The NICE schizophrenia guidelines: the challenge of implementation. Adv Psychiatr Treat 2004;10:403-412. – reference: Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-760. – reference: Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100. – reference: Lamberti JS, Olson D, Crilly JF et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163:1273-1276. – reference: Brown S, Birtwistle J, Roe L et al. The unhealthy lifestyles of people with schizophrenia. Psychol Med 1999;29:697-701. – reference: Patrick V, Schleifer SJ, Nurenberg JR et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv 2006;57:21-23. – reference: Taylor D, Young C, Esop R et al. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;85:152-156. – reference: Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-480. – volume: 181 start-page: 544 year: 2004 end-page: 548 article-title: Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement publication-title: Med J Aust – volume: 80 start-page: 19 year: 2005 end-page: 32 article-title: Prevalence of the metabolic syndrome in patients with schizophrenia : Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES 111 publication-title: Schizophr Res – volume: 332 start-page: 833 year: 2006 end-page: 836 article-title: Hypertension and ethnic group publication-title: Br Med J – volume: 65 start-page: 547 year: 2004 end-page: 550 article-title: Hyperlipidaemia in persons using antipsychotic medication: a general population based birth cohort study publication-title: J Clin Psychiatry – volume: 19 start-page: 182 year: 2005 end-page: 186 article-title: Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs publication-title: J Psychopharmacol – volume: 68 start-page: 22 year: 2007 end-page: 28 article-title: Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review publication-title: J Clin Psychiatry – volume: 68 start-page: 1045 year: 2007 end-page: 1055 article-title: Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey publication-title: J Clin Psychiatry – volume: 85 start-page: 152 year: 2004 end-page: 156 article-title: Testing for diabetes in hospitalised patients prescribed antipsychotic drugs publication-title: Br J Psychiatry – volume: 110 start-page: 299 year: 2004 end-page: 305 article-title: Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs publication-title: Acta Psychiatr Scand – year: 2001 – volume: 33 start-page: 1397 year: 2007 end-page: 1401 article-title: A UK audit of screening for the metabolic side effects of antipsychotics in community patients publication-title: Schizophr Bull – volume: 6 start-page: 6 year: 2003 end-page: 7 article-title: Strategies for implementing evidence‐based practices in routine mental health settings publication-title: Evid Based Ment Health – volume: 287 start-page: 356 year: 2002 end-page: 359 article-title: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey publication-title: JAMA – volume: 83 start-page: 87 year: 2006 end-page: 93 article-title: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication publication-title: Schizophr Res – volume: 49 start-page: 753 year: 2004 end-page: 760 article-title: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome publication-title: Can J Psychiatry – volume: 57 start-page: 21 year: 2006 end-page: 23 article-title: An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital publication-title: Psychiatr Serv – volume: 21 start-page: 93 year: 2006 end-page: 98 article-title: High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia publication-title: Int Clin Psychopharmacol – volume: 64 start-page: 242 year: 2007 end-page: 249 article-title: Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database publication-title: Arch Gen Psychiatry – volume: 29 start-page: 697 year: 1999 end-page: 701 article-title: The unhealthy lifestyles of people with schizophrenia publication-title: Psychol Med – volume: 24 start-page: S31 issue: suppl. 1 year: 2004 end-page: S37 article-title: Implementing clinical guidelines: current evidence and future implications publication-title: J Contin Educ Health Prof – volume: 27 start-page: 596 year: 2004 end-page: 601 article-title: Consensus development conference on antipsychotic drugs and obesity and diabetes publication-title: Diabetes Care – volume: 24 start-page: 1199 year: 2007 end-page: 1204 article-title: How does ethnicity affect the association between obesity and diabetes? publication-title: Diabet Med – volume: 68 start-page: 8 issue: suppl. 4 year: 2007 end-page: 13 article-title: Antipsychotic medications: metabolic and cardiovascular risk publication-title: J Clin Psychiatry – year: 2008 article-title: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 publication-title: Schizophr Res – volume: 41 start-page: 606 year: 2007 end-page: 610 article-title: Obesity and metabolic syndrome in a psychiatric rehabilitation service publication-title: Aust N Z J Psychiatry – year: 2002 – volume: 184 start-page: S80 year: 2004 end-page: S86 article-title: Antipsychotics and diabetes: review of ‐prospective data publication-title: Br J Psychiatry – volume: 10 start-page: 403 year: 2004 end-page: 412 article-title: The NICE schizophrenia guidelines: the challenge of implementation publication-title: Adv Psychiatr Treat – volume: 89 start-page: 91 year: 2007 end-page: 100 article-title: Does antipsychotic polypharmacy increase the risk for metabolic syndrome? publication-title: Schizophr Res – year: 2006 – volume: 64 start-page: 575 year: 2003 end-page: 579 article-title: Metabolic syndrome in patients with schizophrenia publication-title: J Clin Psychiatry – volume: 191 start-page: 23 year: 2007 end-page: 29 article-title: Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community publication-title: Br J Psychiatry – volume: 93 start-page: 572 year: 2008 end-page: 577 article-title: Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism publication-title: J Clin Endocrinol Metab – volume: 23 start-page: 469 year: 2006 end-page: 480 article-title: Metabolic syndrome – a new world‐wide definition. A Consensus Statement from the International Diabetes Federation publication-title: Diabet Med – volume: 163 start-page: 1273 year: 2006 end-page: 1276 article-title: Prevalence of the metabolic syndrome among patients receiving clozapine publication-title: Am J Psychiatry – volume: 285 start-page: 2486 year: 2001 end-page: 2497 article-title: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) publication-title: JAMA – volume: 109 start-page: 433 year: 2004 end-page: 438 article-title: Definition of the metabolic syndrome publication-title: Circulation – volume: 36 start-page: 332 year: 2004 end-page: 346 article-title: Epidemiology and treatment of the metabolic syndrome publication-title: Ann Med – start-page: 7 year: 2003 end-page: 23 – start-page: 7 volume-title: Cardiovascular risk associated with schizophrenia and its treatment year: 2003 ident: e_1_2_9_2_2 – ident: e_1_2_9_6_2 doi: 10.1017/S0033291798008186 – ident: e_1_2_9_16_2 doi: 10.1111/j.1464-5491.2006.01858.x – ident: e_1_2_9_22_2 doi: 10.2337/diacare.27.2.596 – ident: e_1_2_9_24_2 doi: 10.1016/j.schres.2005.12.855 – ident: e_1_2_9_12_2 doi: 10.1080/07853890410031849 – volume: 68 start-page: 8 issue: 4 year: 2007 ident: e_1_2_9_13_2 article-title: Antipsychotic medications: metabolic and cardiovascular risk publication-title: J Clin Psychiatry – ident: e_1_2_9_38_2 doi: 10.1016/j.schres.2005.07.014 – volume: 285 start-page: 2486 year: 2001 ident: e_1_2_9_17_2 article-title: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) publication-title: JAMA doi: 10.1001/jama.285.19.2486 – ident: e_1_2_9_3_2 doi: 10.1001/archpsyc.64.2.242 – ident: e_1_2_9_37_2 doi: 10.1016/j.schres.2006.08.017 – ident: e_1_2_9_35_2 doi: 10.1016/j.schres.2007.12.487 – ident: e_1_2_9_23_2 doi: 10.5694/j.1326-5377.2004.tb06443.x – ident: e_1_2_9_33_2 doi: 10.1097/01.yic.0000188215.84784.17 – ident: e_1_2_9_31_2 doi: 10.1001/jama.287.3.356 – ident: e_1_2_9_21_2 doi: 10.1192/bjp.185.2.152 – ident: e_1_2_9_39_2 doi: 10.1136/bmj.332.7545.833 – ident: e_1_2_9_28_2 doi: 10.1176/appi.ps.57.1.21 – ident: e_1_2_9_9_2 doi: 10.1192/bjp.184.47.s80 – ident: e_1_2_9_30_2 doi: 10.1002/chp.1340240506 – ident: e_1_2_9_19_2 doi: 10.1093/schbul/sbm038 – ident: e_1_2_9_7_2 doi: 10.1210/jc.2007-1167 – ident: e_1_2_9_20_2 doi: 10.1111/j.1600-0447.2004.00372.x – ident: e_1_2_9_32_2 doi: 10.1177/070674370404901106 – ident: e_1_2_9_26_2 doi: 10.1136/ebmh.6.1.6 – ident: e_1_2_9_14_2 doi: 10.4088/JCP.v64n0513 – ident: e_1_2_9_34_2 doi: 10.1176/ajp.2006.163.7.1273 – ident: e_1_2_9_40_2 doi: 10.1111/j.1464-5491.2007.02244.x – ident: e_1_2_9_5_2 doi: 10.4088/JCP.v68n0711 – ident: e_1_2_9_4_2 doi: 10.1192/bjp.bp.106.031716 – ident: e_1_2_9_27_2 doi: 10.1002/14651858.CD000259.pub2 – ident: e_1_2_9_36_2 doi: 10.1080/00048670701392841 – ident: e_1_2_9_8_2 doi: 10.4088/JCP.v65n0415 – ident: e_1_2_9_25_2 doi: 10.1192/apt.10.6.403 – ident: e_1_2_9_11_2 doi: 10.1161/01.CIR.0000111245.75752.C6 – ident: e_1_2_9_15_2 doi: 10.4088/JCP.v68n0103 – ident: e_1_2_9_10_2 doi: 10.1177/0269881105049039 – volume-title: Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care year: 2002 ident: e_1_2_9_18_2 – ident: e_1_2_9_29_2 doi: 10.1002/14651858.CD003030 |
| SSID | ssj0005108 |
| Score | 2.1597223 |
| Snippet | Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients... Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients... The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients prescribed... Objective: The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients... Objective:The aim was to evaluate a quality improvement programme designed to increase screening for the metabolic syndrome in community psychiatric patients... |
| SourceID | proquest pubmed pascalfrancis crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 26 |
| SubjectTerms | Adolescent Adult Aged Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use antipsychotics Benchmarking - standards Biological and medical sciences Body Weight - drug effects Community Mental Health Services - standards Community-Institutional Relations - standards Dose-Response Relationship, Drug Drug Therapy, Combination Drug toxicity and drugs side effects treatment England Female Health Services Accessibility Humans Life Style Male Mass Screening - standards Medical Audit - standards Medical sciences Medical screening Mental disorders Metabolic syndrome Metabolic Syndrome - chemically induced Metabolic Syndrome - diagnosis Metabolic Syndrome - epidemiology Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Mood Disorders - drug therapy Mood Disorders - epidemiology Pharmacology. Drug treatments Physical Examination Psychiatry Psychotic Disorders - drug therapy Psychotic Disorders - epidemiology Quality Assurance, Health Care - standards Quality Indicators, Health Care - standards Quality of care Reference Standards Reminder Systems Retrospective Studies screening Surveys and Questionnaires |
| Title | Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme |
| URI | https://api.istex.fr/ark:/67375/WNG-5M76H6WW-J/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1600-0447.2008.01203.x https://www.ncbi.nlm.nih.gov/pubmed/18582345 https://www.proquest.com/docview/195857652 https://www.proquest.com/docview/19757488 https://www.proquest.com/docview/69261511 |
| Volume | 118 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlhdJLv9u4aVMdSm9ebEuyrN5CaLoEEkrTsHsTsiyD2cQpsReS3vrPO2NpnbqkEEpvBmsWNPs0eiO_GRHyHtayU3VVxRL275gXiYE4yCBxFZBuSQkoqga1xXE-P-WHS7EM-ieshfH9IcYDN1wZQ7zGBW7KbrrIc6yK5lwGSWSaJWyGfBKlW8iPvt50kgLo-aAM2TMkhMupqOfWH5rsVPfR6VeonDQdOK_2t17cRkunLHfYpg4ek9Vmgl6dspqt-3Jmf_zR-_H_eOAJeRTYLN3z8HtK7rn2GXlwFL7XPyc_TyzqemB7pECOKZBNeu56wN1ZY-mmWQJtWmp9nUp_TUf5NYwITV87impdCG-lqyggoQmlY43tPlJDfV3oNW2G85HhuJMG2dm5e0FODz5925_H4dKH2GIrvjg1pc1YVZtMVYwnpXJG2bwGGmuAqjrm0sSYEtJWB5lkzSAfNHWSGWm5KwtRO_aSbLUXrdsmVGWpkxxbxquUO8GUqx2wIc6kyCwvVETk5g_WNnREx4s5zvRvmRF4WKOHw32d6GF9FZF0tPzuu4LcwebDgKHRwFyuUFUnhV4cf9biSObzfLHQhxHZnYBsNMAyZgEMMiI7G9TpEHE6jU2DIHcUWUTejW8hVOD3H9O6izUOkUJCwP77iFxlyHDTiLzyYL6ZXSEKcJ0Anw2QvPO09d7-lxN8fP3PljvkoVfpoEj6DdnqL9fuLVDBvtwdFvkveHlOpQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQKwEX3o9QaH1A3LLKw45jblWhLKW7QrTV7s1yHEeKuk1RNyu13PjnzMTelKAiVYhbpHhW8uzM-BvnmxlC3oIvW1mVZSjg_A5ZHmmIgykkrhzSLSHAisqObTHNxifsYM7nfhwQ1sK4_hD9hRt6Rhev0cHxQnro5RmWRTMmPCcyTqJ0BIByEwd8o5d--HbdSwqMz4VlyJ8hJZwPaT03_tLgrNpEtV8id1IvQX2Vm3txEzAd4tzuoNp_SBbrLTp-yulo1RYj8-OP7o__SQePyAMPaOmus8DH5I5tnpC7E__J_in5eWSQ2gMnJAV8TAFv0jPbguktakPX_RJo3VDjSlXaK9ozsGGF7_u6pEjYhQhX2JKCMdS-eqw2y_dUU1caekXr7oqku_Gknnl2Zp-Rk_2Px3vj0M99CA124wtjXZgkLSudyDJlUSGtliarAMlqQKs2tXGkdQGZq4VkskohJdRVlGhhmC1yXtn0Odlozhv7klCZxFYw7BovY2Z5Km1lARCxVPDEsFwGRKz_YWV8U3SczbFQvyVHoGGFGvYjO1HD6jIgcS_53TUGuYXMu86IegF9cYrEOsHVbPpJ8YnIxtlspg4Csj2wsl4AK5k5gMiAbK3NTvmgs1TYNwjSR54EZKd_C9ECPwHpxp6vcIngAmL231dkMkGQGwfkhbPm693lPAfVcdBZZ5O33rba3ft6hI-v_llyh9wbH08O1eHn6Zctct-RdpAz_ZpstBcr-waQYVtsdx7_C0cPUr4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqkFAvLf0kpQUfqt6yyocdJ9wQdLvQskKlaPdmOY4jRQsBsVkJeus_70zsDU0FEkLcIsWzkmefx2-cN2NCPsNaNllZFL6A_dtnaaAgDsaQuHJIt4QAFBWt2mKcjE7Z4ZRPnf4Ja2Fsf4juwA1XRhuvcYFfFmV_kSdYFc2YcJLIMAriAfDJVZYEKSZi-z9vW0kB9mxUhvQZMsJpX9Vz5y_1tqpV9Po1SifVHLxX2msv7uKlfZrb7lPDl2S2nKGVp8wGiyYf6N__NX98GheskxeOztJdi79X5JmpX5O1I_fB_g35c6JR2AP7IwV2TIFt0nPTAPDOKk2X3RJoVVNtC1WaG9rpr2GE6_o6pyjXhfiWm4ICFCpXO1bp-Q5V1BaG3tCqPSBpzzup052dm7fkdPj1197Id7c--Bp78fmhynUUF6WKsiJmQZ4ZlemkBB6rgKua2ISBUjnkrQZSyTKGhFCVQaSEZiZPeWnid2SlvqjNBqFZFBrBsGd8FjLD48yUBugQiwWPNEszj4jlHyy1a4mON3OcyX9SI_CwRA-7CzvRw_LaI2FneWnbgjzA5kuLoc5AXc1QVie4nIy_SX4kklEymchDj2z1QNYZYB0zBwrpkc0l6qQLOXOJXYMgeeSRR7a7txAr8AOQqs3FAocILiBi3z8iySKkuKFH3lsw384u5Sm4joPPWkg-eNpyd-_4BB8_PNpym6wd7w_lj4Px903y3Cp2UDD9kaw0VwvzCWhhk2-16_0vHYBRdg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Screening+for+the+metabolic+syndrome+in+community+psychiatric+patients+prescribed+antipsychotics%3A+a+quality+improvement+programme&rft.jtitle=Acta+psychiatrica+Scandinavica&rft.au=Barnes%2C+T.+R.+E.&rft.au=Paton%2C+C.&rft.au=Hancock%2C+E.&rft.au=Cavanagh%2C+M.%E2%80%90R.&rft.date=2008-07-01&rft.issn=0001-690X&rft.eissn=1600-0447&rft.volume=118&rft.issue=1&rft.spage=26&rft.epage=33&rft_id=info:doi/10.1111%2Fj.1600-0447.2008.01203.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1600_0447_2008_01203_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0001-690X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0001-690X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0001-690X&client=summon |